RxDoctor Payments Data

Krishan Kalra, MD

Cardiovascular Disease · Trenton, NJNPI 1871537472

Payments from drug & device makers

$2,685in general payments, 2019–2025

Across 167 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$474
  • Merck$304
  • Pfizer$272
  • Amgen$219
  • Johnson & Johnson$191
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$180
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,685 in reported general payments places this provider in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$239,342
Medicare patients
426
Services billed
3,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban371$312,016
EntrestoSacubitril/Valsartan65$66,532
MultaqDronedarone Hcl42$44,096
FarxigaDapagliflozin Propanediol36$29,080
XareltoRivaroxaban20$19,557
Repatha SureclickEvolocumab20$18,965
Repatha SyringeEvolocumab18$13,883
Pitavastatin Calcium20$7,631
Metoprolol Succinate366$5,642
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine13$4,104
Nifedipine ErNifedipine85$3,619
Atorvastatin Calcium247$3,176
ClopidogrelClopidogrel Bisulfate205$2,730
Digoxin64$2,208
Ranolazine ErRanolazine12$1,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$272$312,016371 claims
NovartisEntresto$474$66,53265 claims
Sanofi-aventis U.S. LLCMultaq$22$44,09642 claims
AstraZenecaFarxiga$69$29,08036 claims
Johnson & JohnsonXarelto$191$19,55720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Trenton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →